BNTX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

BN

Mkt Cap

$22.02B

Volume

1.01M

Next Earnings

November 3rd

Loading chart

BN

BNTXBioNTech SE American Depositary Share

BNTX

Pay with—

Available Balance0.00

BN

Mkt Cap

$22.66B

Volume

1.01M

Next Earnings

November 3rd

Chart Earnings News About Insider Filings

Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?The article compares Bristol-Myers Squibb and Johnson & Johnson as healthcare investment options. BMY trades at a cheaper valuation (9.3x forward P/E vs JNJ's 21x) with a higher dividend yield of 4.16%, but faces patent cliffs and pricing pressures. JNJ offers greater revenue scale ($94.2B vs $48.2B), diversified business segments, and a 64-year dividend growth streak, making it the recommended choice for 2026 despite its premium valuation.The Motley Fool · Oct 17, 2026

MRNA Stock Gains Over $4B in a Week: Time to Buy, Hold or Sell?Moderna's stock gained over 5% in a week, adding $4.2 billion in market value, driven by positive phase III melanoma results for its cancer therapy intismeran and inclusion in the Nasdaq-100 Index. While the company shows promise in oncology and respiratory vaccines, its 625% YTD rally has resulted in a premium valuation that leaves it vulnerable to disappointment. The stock is rated a Hold, with short-term investors advised to book profits while long-term investors may consider holding for future growth opportunities.Zacks Investment Research · Oct 13, 2026

Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?The article compares Bristol Myers Squibb and Pfizer as healthcare investment options for 2026. Both face patent cliffs and regulatory pressures, but Pfizer is recommended as the better choice due to its clearer post-patent roadmap, growing non-COVID products, obesity drug positioning, and committed dividend protection. Bristol Myers Squibb shows near-term momentum improvements but faces longer-term revenue uncertainty from patent losses and drug pricing reforms.The Motley Fool · Oct 9, 2026

Moderna vs. BioNTech: Which mRNA Stock Is the Better Buy Now?Both Moderna and BioNTech are transitioning beyond COVID-19 vaccines into oncology and other therapeutic areas. Moderna has already commercialized RSV and flu vaccines with positive intismeran cancer therapy results, while BioNTech relies more heavily on Comirnaty and has a broader but less advanced oncology pipeline. Moderna is rated as the better investment choice despite trading at a premium valuation, given its further-along transition away from COVID-19 dependency.Zacks Investment Research · Sep 30, 2026

Head and Neck Squamous Cell Carcinoma (HNSCC) - Market Insights, Epidemiology, and Market Forecast - 2036 | Set to Reach $2.56 Billion as HPV-Targeted Vaccines Reshape CareThe HNSCC market is projected to grow from $850 million in 2025 to $2.56 billion by 2036 (10.5% CAGR), driven by HPV-targeted vaccines, checkpoint inhibitors, and biomarker-led patient selection. The US will remain the largest market at $2.082 billion. Key therapies include KEYTRUDA and OPDIVO, with emerging candidates like petosemtamab and amivantamab showing promise in clinical development.GlobeNewswire Inc. · Sep 30, 2026

Pfizer Stock Rises Almost 9% in 3 Months: Time to Buy, Hold or Exit?Pfizer's stock has risen 8.6% in three months as investors gain confidence in the company's ability to offset declining COVID-19 product sales with growth from non-COVID products, which grew 18% operationally in Q2. The company is pursuing ambitious pipelines in oncology and obesity, with plans for 10 Phase III studies for berobenatide targeting first approvals in 2028. However, Pfizer faces headwinds from a $1.1B revenue impact from patent expirations and expects 2026 revenue to decline slightly to $60.5-$62.5 billion. Despite these challenges, the stock trades at an attractive valuation with a 6.2% dividend yield, and analysts maintain a Hold rating with expectations for high single-digit revenue growth from 2029 onward.Zacks Investment Research · Sep 9, 2026

Why Pfizer Stock Was so Healthy in AugustPfizer stock surged nearly 14% in August following better-than-expected Q2 earnings (revenue $15B vs. $14.4B expected, EPS $0.77 vs. $0.68 expected) and raised full-year revenue guidance. The company also achieved regulatory victories with EMA validation for a Lyme disease treatment and FDA approval for an updated COVID vaccine. Despite investor impatience over the lack of new blockbuster products, the analyst views Pfizer as undervalued with a promising pipeline from recent acquisitions.The Motley Fool · Sep 8, 2026

BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now?BioNTech and Moderna, both mRNA vaccine pioneers during the pandemic, are now pivoting to cancer vaccines as COVID revenue declines. Moderna is favored due to stronger recent clinical progress, including positive phase 3 results for its personalized cancer vaccine intismeran autogene and FDA approval for mFLUSIVA flu vaccine. While BioNTech has a deep pipeline including pumitamig, it has yet to deliver comparable phase 3 wins. Moderna's $61.2 billion market cap reflects investor confidence in its near-term commercialization prospects versus BioNTech's $26 billion valuation.The Motley Fool · Sep 3, 2026

Advanced Endometrial Cancer Clinical Trial Pipeline Analysis: 25+ Key Companies Shaping the Future of Advanced Endometrial Cancer Therapeutics Space | DelveInsightDelveInsight released a comprehensive analysis of the advanced endometrial cancer clinical trial pipeline, identifying 25+ active pharmaceutical companies developing 26+ pipeline drugs. The report highlights emerging therapies including immunotherapies, targeted agents, and antibody-drug conjugates (ADCs) from major players like Pfizer, Genmab, and Incyte Corporation. Recent developments include FDA Fast Track designation for Faeth Therapeutics' PIKTOR combination therapy and positive Phase III results for Merck's sacituzumab tirumotecan, indicating significant momentum in reshaping the advanced endometrial cancer treatment landscape.GlobeNewswire Inc. · Sep 3, 2026

Is BioNTech Stock a No-Brainer Buy on the Dip?BioNTech stock has underperformed significantly, losing 70% over five years as COVID-19 vaccine sales declined. However, the company's mRNA platform is gaining renewed investor interest following Moderna and Merck's successful cancer vaccine trial. BioNTech's diverse pipeline of oncology candidates, including BNT113, BNT116, and pumitamig, could drive future growth, though clinical setbacks remain a risk. The stock appears somewhat attractive but is not a guaranteed buy given its $25.4B valuation and lack of consistent profitability.The Motley Fool · Sep 2, 2026

to start trading

BN

BNTXBioNTech SE American Depositary Share

BNTX

Pay with—

Available Balance0.00

Your PositionYou don't own any BNTX yet.

Related Tickers

Earnings